Revance Therapeutics Inc Intends To Continue Processing Payments For Current OPUL Customers Through January 31, 2024; Expects To Record A Restructuring Charge In Connection With Such Activities Of Up To $7M
Portfolio Pulse from Benzinga Newsdesk
Revance Therapeutics Inc. plans to continue processing payments for current OPUL customers through January 31, 2024. The company expects to record a restructuring charge of up to $7M in connection with these activities, according to an SEC filing.
September 19, 2023 | 1:13 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Revance Therapeutics Inc. is expected to incur a restructuring charge of up to $7M due to its decision to continue processing payments for OPUL customers through January 2024.
The decision to continue processing payments for OPUL customers will result in a restructuring charge for Revance Therapeutics. This additional expense could negatively impact the company's financial performance in the short term, potentially leading to a decrease in its stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100